



## Targeting tau protein with small molecule inhibitors for neurodegeneration


Oligomerix® is developing small molecule candidates based on tau self-association inhibition to achieve disease modification for Alzheimer's disease (AD) and related neurodegenerative diseases.

### Oligomerix Overview

- Founded in 2006 by pioneers in targeting tau for drug discovery
- Private company - recently received \$3.19M NIH grant; \$21.9M raised to date
- Lead program candidate validated in two transgenic models of tauopathy
- Publications in leading neurology peer-reviewed journals (Journal of Alzheimer's Disease, Neurobiology of Aging)
- Presentations at world-class conferences (AAIC, Clinical Trials on Alzheimer's Disease Conference, SfN)
- Strong IP portfolio in the U.S. and internationally; four issued patents and one trademark, additional filings pending
- Experienced management team and board members with deep pharma background

### Unleashing the Potential of Tau Oligomer Inhibition

- To date, most therapeutic studies in clinic for AD have focused on beta amyloid, but had limited success in patients. Tau protein dysfunction and aggregation are central to AD and other tauopathies including progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD).
- Oligomerix's lead compound is a preclinical small molecule inhibitor of tau self-association targeting the beginning of the tau aggregation cascade, that has demonstrated *in vivo* efficacy in two transgenic mouse models.
- With a highly differentiated strategy for targeting tau pathophysiology, **Oligomerix is planning to begin clinical testing in early 2022.**



### Management Team

- James G. Moe, President and Chief Executive Officer\*
- William Erhardt, Chief Medical Officer
- Eliot J. Davidowitz, Chief Scientific Officer\*
- Jack Pasini, Chief Commercial Officer\*
- Robert Foerster, Chief Financial Officer
- Paul Ginsburg, IP Counsel

\*Board Directors

### Additional Board Members

- Victor P. Micati, Chairman
- David Dantzker, Director
- Douglas N. Durand, Director
- Jeffrey N. Bluestein, Director

**Headquarters:** White Plains, New York, with laboratory facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.

Website: <http://oligomerix.com>

Twitter: [@Oligomerix](https://twitter.com/Oligomerix)

LinkedIn: [Oligomerix, Inc.](https://www.linkedin.com/company/oligomerix)

### Media Contact

Michelle Linn, Bioscribe  
774-696-3803  
[michelle@bioscribe.com](mailto:michelle@bioscribe.com)

Oligomerix, Inc.  
2 Westchester Park Drive, Suite 208 White Plains, NY 10604  
Copyright 2020 Oligomerix, Inc.